How to determine post-RCHOP therapy for risk-tailored adult patients with diVuse large B-cell lymphoma, addition of maintenance rituximab or observation: Multicenter experience

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 1, 2012, Pages 125-132

  Huang, Bin Tao ^a   Zeng, Qing Chun ^b   Yu, Jessica ^c   Xiao, Zhen ^a   Li, Bing Sheng ^d   Zhang, Chun Lai ^e   Ji, Hong Bo ^f  

^a INNER MONGOLIA MEDICAL COLLEGE   (China)

^b GUANGDONG MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d Huizhou Medicine Institute   (China)

^e THE FIRST PEOPLE S HOSPITAL OF CHENZHOU   (China)

^f Chifeng Municipal Hospital   (China)

Author keywords

Adult patients; DiVuse large B cell lymphoma; International Prognostic Index; RCHOP 14; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADOLESCENT; ADULT; AGRANULOCYTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CHEMOTHERAPY INDUCED EMESIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DOSE RESPONSE; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; HUMAN; INFECTION; KIDNEY FAILURE; LARGE CELL LYMPHOMA; LIVER DYSFUNCTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SURVIVAL RATE; SURVIVAL TIME;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; PREDNISONE; VINCRISTINE; YOUNG ADULT;

EID: 84857047323     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-011-1074-1     Document Type: Article

References (23)

1. Benekli M, Hahn T, ShaW F, Qureshi A, Alam AR, Czuczman MS et al (2003) EVect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin's lymphoma patients. Bone Marrow Transpl 32:139-143 (Pubitemid 36903436)
2. Cheson BD, Horning SJ, CoiYer B et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 17:1244-1253 (Pubitemid 29162950)
3. Gottlieb JA, Gutterman JU, McCredie KB, Rodriguez V, Frei E 3rd (1973) Chemotherapy of malignant lymphoma with adriamycin. Cancer Res 33:3024-3028
4. Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB et al (2006) Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diVuse large B-cell lymphoma. J Clin Oncol 24:3121-3127 (Pubitemid 46638950)
5. Harris NL, JaVe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J et al (1999) World Health Organization classiWcation of neoplastic disease of hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849
6. Hochster H, Weller E, Gascoyne RD, Habermann TM, Gordon LI, Ryan T et al (2009) Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol 27:1607-1614
7. Horwitz SM, Negrin RS, Blume KG, Breslin S, Stuart MJ, Stockerl- Goldstein KE et al (2004) Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 103:777-783 (Pubitemid 38129532)
8. Josting A, Reiser M, RueVer U, Salzberger B, Diehl V, Engert A (2000) Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure? J Clin Oncol 18:332-339 (Pubitemid 30056422)
9. Kewalramani T, Zelenetz AD, Hedrick EE, Donnelly GB, Hunte S, Priovolos AC, Qin J, Lyons NC et al (2000) High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis. Blood 96:2399-2404
10. Khouri IF, Saliba RM, Hosing C, Okoroji GJ, Acholonu S, Anderlini P et al (2005) Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol 23:2240-2247 (Pubitemid 46218716)
11. Koivula S, Valo E, Raunio A, Hautaniemi S, Leppä S (2011) Rituximab regulates signaling pathways and alters gene expression associated with cell death and survival in diVuse large B-cell lymphoma. Oncol Rep 25:1183-1190
12. Lister TA, Crowther D, SutcliVe SB, Glatstein E, Canellos GP, Young RC et al (1989) Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 7:1630-1636 (Pubitemid 19272832)
13. Mark M, Cerny T (2010) New treatments of malignant lymphoma- a review. Ther Umsch 67:537-543
14. McKelvey EM, Gottlieb JA, Wilson HE et al (1976) Hydroxydaunomycin (adriamycin) combination chemotherapy in malignant lymphoma. Cancer 38:1484-1493
15. Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM et al (1998) Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 339:21-26 (Pubitemid 28304493)
16. Moskowitz CH, Bertino JR, Glassman JR, Hedrick EE, Hunte S, Coady-Lyons N et al (1999) Ifosfamide, carboplatin, and etoposide: a highly eVective cytoreduction and peripheral-blood progenitor- cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 17:3776-3785
17. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapysensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545
18. Plosker GL, Figgitt DP (2003) Rituximab: a review of its use in non- Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 63:803-843 (Pubitemid 36432084)
19. Rosenberg S, Berard C, Brown B Jr, Burke J, Dorfman R, Glatstein E et al (1982) National Cancer Institute sponsored study of classiWcations of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic ClassiWcation Project. Cancer 49:2112-2135
20. Salles G, Seymour JF, OVner F, López-Guillermo A, Belada D, Xerri L et al (2011) Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377:42-51
21. Shipp MA, Harrington DP (1993) A predictive model for aggressive NHL: the international non-Hodgkin's lymphoma prognostic factors project. N Engl J Med 329:987-994 (Pubitemid 23307906)
22. Vose JM, Zhang MJ, Rowlings PA, Lazarus HM, Bolwell BJ, Freytes CO et al (2001) Autologous transplantation for diVuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the autologous blood and marrow transplant registry. J Clin Oncol 19:406-413 (Pubitemid 32112852)
23. Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M et al (2010) Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 28:2373-2380